Current trendAnalogs and fibrosis regression in hepatitis BAnalogues et régression de la fibrose dans l’hépatite B
Introduction
The goal of therapy for hepatitis B is to improve survival and quality of life by preventing progression of the disease to severe fibrosis, cirrhosis, decompensated cirrhosis, end-stage liver disease, hepatocellular carcinoma and death. This goal can be achieved if hepatitis B virus (HBV) replication can be suppressed in a sustained manner, as this results in reductions in both histological necroinflammatory activity and the fibrosis of chronic hepatitis. This, in turn, will lower the risk of cirrhosis as well as the risk of hepatocellular carcinoma in non-cirrhotic patients and probably — albeit to a lesser extent — in cirrhotic patients as well [1].
Two different types of drugs can be used in the treatment of chronic hepatitis B: interferon and nucleoside/nucleotide analogs. Analog therapies against HBV belong to three classes:
- •
l-nucleosides (lamivudine, telbivudine and emtricitabine);
- •
deoxyguanosine analogs (entecavir);
- •
acyclic nucleoside phosphonates (adefovir and tenofovir).
All of these drugs (except emtricitabine) have been approved in Europe for HBV treatment. Their efficacy in reducing HBV replication has been demonstrated in randomized controlled trials lasting 1 year (2 years for telbivudine). Longer-term results (up to 5 years) are available for lamivudine, adefovir, entecavir and telbivudine in patient subgroups [2]. The objective of this report is to review fibrosis regression in these studies in relation to viral suppression and the occurrence of resistance mutation.
Section snippets
Lamivudine and fibrosis regression
Lamivudine results in a rapid decrease in serum HBV DNA concentrations. Using different HBV DNA assays, undetectable HBV DNA was achieved in 1 year in up to 98% with the first-generation assay, and in 36–40% with the more sensitive polymerase chain reaction (PCR) assays in HBe antigen (HBeAg)-positive patients and around 72% with PCR assays in HBeAg-negative patients [2], [3], [4], [5]. Loss of HBeAg was found in 17–33% of patients after 1 year and HBeAg seroconversion was observed in 16–21%.
Adefovir dipivoxil and fibrosis regression
Adefovir dipivoxyl has proved effective against HBeAg-positive and HBeAg-negative chronic hepatitis B in randomized controlled trials [11], [12]. In HBeAg-positive patients, adefovir treatment led to undetectable HBV DNA with PCR assays in 21% of patients after 1 year, while 24% showed HBeAg loss and 12% had seroconversion to HBe antibodies [11]. In a small subset of patients who took adefovir for 5 years, undetectable HBV DNA was observed in 39% of patients, 58% showed HBeAg loss, 48% had
Telbivudine and fibrosis regression
Telbivudine proved effective in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B in a large phase-III, randomized, controlled trial [6]. After 1 year of telbivudine, HBV DNA was undetectable by PCR assay (lowest limit of quantification is 300 copies/mL) in 60% of HBeAg-positive patients and 88% of HBeAg-negative patients, proportions that were significantly larger than seen with lamivudine (40 and 71%, respectively). In addition, 26% of patients had HBeAg loss and 22% had
Entecavir and fibrosis regression
Entecavir has proved effective against HBeAg-positive and HBeAg-negative chronic hepatitis B, with a good resistance profile in randomized controlled trials [7], [8]. In lamivudine-refractory patients, entecavir has been shown to be effective after 1 year, although extended duration of treatment led to a high rate of resistance mutation that, in turn, led to virological rebound [19].
In naive patients, 1 year of entecavir led to undetectable HBV DNA on PCR assays (< 300 copies/mL) in 67% of
Tenofovir disoproxil fumarate and fibrosis regression
Tenofovir has also been shown to be effective against HBeAg-positive and HBeAg-negative chronic hepatitis B, with an excellent resistance profile in randomized controlled trials [14]. In fact, no resistance mutation has been described so far.
In naive patients, 1 year of tenofovir resulted in undetectable HBV DNA on PCR assays (< 400 copies/mL) in 76% of HBeAg-positive and 93% of HBeAg-negative patients, percentages significantly higher than seen in the adefovir group (13 and 63%, respectively).
Assessment of liver fibrosis
Liver biopsy is still recommended for determining the degree of necroinflammation and fibrosis in the pretherapeutic assessment of hepatitis B [2]. However, the size of the needle biopsy needs to be large enough to precisely determine the degree of liver injury and fibrosis, and the technique is invasive, costly, and subject to sampling error and poor intra- and interobserver concordance [21], [22], [23], [24], [25], [26], [27]. Yet, although liver biopsy remains the primary endpoint tool for
Conclusion
There is considerable evidence that HBV treatment with analogs improves liver fibrosis and histological activity. Despite the use of different definitions of fibrosis regression across studies, no significant differences in fibrosis improvement were found after 1 year of treatment with the five approved drugs currently available in Europe. Despite a higher rate of undetectable HBV DNA among HBeAg-negative, compared with HBeAg-positive, naive patients, there was no major difference in improvement
Conflicts of interest
M. Bourlière, A. Kahloun and G. Gascou-Tessonier have no conflicts of interest.
References (33)
EASL Clinical Practice Guidelines: management of chronic hepatitis B
J Hepatol
(2009)- et al.
Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B
J Hepatol
(2005) - et al.
Histological outcome during long-term lamivudine therapy
Gastroenterology
(2003) - et al.
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
Gastroenterology
(2006) - et al.
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B
Gastroenterology
(2006) - et al.
Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver
Lancet
(1986) - et al.
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection
Am J Gastroenterol
(2002) - et al.
Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease
J Hepatol
(2003) - et al.
Sampling variability of liver fibrosis in chronic hepatitis C
Hepatology
(2003) - et al.
Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis B e antigen
Lancet
(1998)